138 related articles for article (PubMed ID: 32132105)
1. Single-Cell Immune Competency Signatures Associate with Survival in Phase II GVAX and CRS-207 Randomized Studies in Patients with Metastatic Pancreatic Cancer.
Nair N; Chen SY; Lemmens E; Chang S; Le DT; Jaffee EM; Murphy A; Whiting C; Müller T; Brockstedt DG
Cancer Immunol Res; 2020 May; 8(5):609-617. PubMed ID: 32132105
[TBL] [Abstract][Full Text] [Related]
2. Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer.
Le DT; Wang-Gillam A; Picozzi V; Greten TF; Crocenzi T; Springett G; Morse M; Zeh H; Cohen D; Fine RL; Onners B; Uram JN; Laheru DA; Lutz ER; Solt S; Murphy AL; Skoble J; Lemmens E; Grous J; Dubensky T; Brockstedt DG; Jaffee EM
J Clin Oncol; 2015 Apr; 33(12):1325-33. PubMed ID: 25584002
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer.
Tsujikawa T; Crocenzi T; Durham JN; Sugar EA; Wu AA; Onners B; Nauroth JM; Anders RA; Fertig EJ; Laheru DA; Reiss K; Vonderheide RH; Ko AH; Tempero MA; Fisher GA; Considine M; Danilova L; Brockstedt DG; Coussens LM; Jaffee EM; Le DT
Clin Cancer Res; 2020 Jul; 26(14):3578-3588. PubMed ID: 32273276
[TBL] [Abstract][Full Text] [Related]
4. A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction.
Le DT; Brockstedt DG; Nir-Paz R; Hampl J; Mathur S; Nemunaitis J; Sterman DH; Hassan R; Lutz E; Moyer B; Giedlin M; Louis JL; Sugar EA; Pons A; Cox AL; Levine J; Murphy AL; Illei P; Dubensky TW; Eiden JE; Jaffee EM; Laheru DA
Clin Cancer Res; 2012 Feb; 18(3):858-68. PubMed ID: 22147941
[TBL] [Abstract][Full Text] [Related]
5. Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer.
Shindo Y; Hazama S; Suzuki N; Iguchi H; Uesugi K; Tanaka H; Aruga A; Hatori T; Ishizaki H; Umeda Y; Fujiwara T; Ikemoto T; Shimada M; Yoshimatsu K; Takenouchi H; Matsui H; Kanekiyo S; Iida M; Koki Y; Arima H; Furukawa H; Ueno T; Yoshino S; Fujita T; Kawakami Y; Nakamura Y; Oka M; Nagano H
J Exp Clin Cancer Res; 2017 Feb; 36(1):36. PubMed ID: 28241889
[TBL] [Abstract][Full Text] [Related]
6. Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study).
Le DT; Picozzi VJ; Ko AH; Wainberg ZA; Kindler H; Wang-Gillam A; Oberstein P; Morse MA; Zeh HJ; Weekes C; Reid T; Borazanci E; Crocenzi T; LoConte NK; Musher B; Laheru D; Murphy A; Whiting C; Nair N; Enstrom A; Ferber S; Brockstedt DG; Jaffee EM
Clin Cancer Res; 2019 Sep; 25(18):5493-5502. PubMed ID: 31126960
[TBL] [Abstract][Full Text] [Related]
7. Characterization of a whole blood assay for quantifying myeloid-derived suppressor cells.
Apodaca MC; Wright AE; Riggins AM; Harris WP; Yeung RS; Yu L; Morishima C
J Immunother Cancer; 2019 Aug; 7(1):230. PubMed ID: 31462270
[TBL] [Abstract][Full Text] [Related]
8. Immune Therapy in Pancreatic Cancer: Now and the Future?
Zhang Y; Choi M
Rev Recent Clin Trials; 2015; 10(4):317-25. PubMed ID: 26374557
[TBL] [Abstract][Full Text] [Related]
9. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
10. Novel agents for the treatment of pancreatic cancer.
Brennan GT; Relias V; Saif MW
JOP; 2014 Mar; 15(2):110-3. PubMed ID: 24618430
[TBL] [Abstract][Full Text] [Related]
11. TGF-β blockade depletes T regulatory cells from metastatic pancreatic tumors in a vaccine dependent manner.
Soares KC; Rucki AA; Kim V; Foley K; Solt S; Wolfgang CL; Jaffee EM; Zheng L
Oncotarget; 2015 Dec; 6(40):43005-15. PubMed ID: 26515728
[TBL] [Abstract][Full Text] [Related]
12. Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy.
Amedei A; Niccolai E; Prisco D
Hum Vaccin Immunother; 2014; 10(11):3354-68. PubMed ID: 25483688
[TBL] [Abstract][Full Text] [Related]
13. Using Quantitative Seroproteomics to Identify Antibody Biomarkers in Pancreatic Cancer.
Jhaveri DT; Kim MS; Thompson ED; Huang L; Sharma R; Klein AP; Zheng L; Le DT; Laheru DA; Pandey A; Jaffee EM; Anders RA
Cancer Immunol Res; 2016 Mar; 4(3):225-33. PubMed ID: 26842750
[TBL] [Abstract][Full Text] [Related]
14. Synergistic anti-pancreatic cancer immunological effects by treatment with reduced expression in immortalized cells/dickkopf-3 protein and peripheral blood mononuclear cells.
Uchida D; Shiraha H; Kato H; Sawahara H; Nagahara T; Iwamuro M; Kataoka J; Horiguchi S; Watanabe M; Takaki A; Nouso K; Nasu Y; Kumon H; Yamamoto K
J Gastroenterol Hepatol; 2016 Jun; 31(6):1154-9. PubMed ID: 26643412
[TBL] [Abstract][Full Text] [Related]
15. Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy.
Farsaci B; Donahue RN; Grenga I; Lepone LM; Kim PS; Dempsey B; Siebert JC; Ibrahim NK; Madan RA; Heery CR; Gulley JL; Schlom J
Cancer Immunol Res; 2016 Sep; 4(9):755-65. PubMed ID: 27485137
[TBL] [Abstract][Full Text] [Related]
16. T-Helper 1 Immune Response in Metastatic Lymph Nodes of Pancreatic Ductal Adenocarcinoma: A Marker For Prolonged Survival.
Nizri E; Sternbach N; Bar-David S; Ben-Yehuda A; Gerstenhaber F; Ofir T; Wolf I; Weiner G; Lahat G; Klausner J
Ann Surg Oncol; 2018 Feb; 25(2):475-481. PubMed ID: 29124488
[TBL] [Abstract][Full Text] [Related]
17. Q&A: Evidence presenter. Interview by Marian Turner.
Palucka K
Nature; 2013 Dec; 504(7480):S9. PubMed ID: 24352364
[No Abstract] [Full Text] [Related]
18. The metastasis status and tumor burden-associated CA125 level combined with the CD4/CD8 ratio predicts the prognosis of patients with advanced pancreatic cancer: A new scoring system.
Yang C; Cheng H; Luo G; Lu Y; Guo M; Jin K; Wang Z; Yu X; Liu C
Eur J Surg Oncol; 2017 Nov; 43(11):2112-2118. PubMed ID: 28802662
[TBL] [Abstract][Full Text] [Related]
19. Frequency of Immune Cell Subtypes in Peripheral Blood Correlates With Outcome for Patients With Metastatic Breast Cancer Treated With High-Dose Chemotherapy.
Lafrenie RM; Speigl L; Buckner CA; Pawelec G; Conlon MS; Shipp C
Clin Breast Cancer; 2019 Dec; 19(6):433-442. PubMed ID: 31383605
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Prognostic Immune Signatures in Patients with Breast, Colorectal and Pancreatic Cancer Receiving Chemotherapy.
Vogl UM; Öhler L; Rasic M; Frischer JM; Modak M; Stöckl J
Anticancer Res; 2017 Apr; 37(4):1947-1955. PubMed ID: 28373465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
